Table 1.

Clinical and pathologic characteristics of esophageal adenocarcinomas in relation to PD-1, PD-L1, and PD-L2 expression

All cases, n (%)PD-L2+ cases ≥ 1 core, n (%)PPD-L2+ cases all cores, n (%)PPD-L1+ cases, n (%)PPD-1+ cases, n (%)P
All cases354 (100)183/354 (51.7)70/354 (19.8)62/344 (18.0)212/349 (60.7)
Sex
 Male292 (82.5)149 (51.0)57 (19.5)51 (17.7)176 (61.3)
 Female62 (17.5)34 (54.8)0.86213 (21.0)0.86111 (18.1)1.00036 (58.1)0.668
Age, y
 Median (IQR)67 (60–75)670.15267.70.39568.20.192670.405
Body mass index, kg/m2
 Median (IQR)27.7 (25.1–31.6)28.40.50728.50.63929.10.73728.70.576
History of smoking
 No101 (28.9)52 (51.5)23 (22.8)18 (18.4)57 (56.4)
 Yes249 (71.1)130 (52.2)0.90247 (18.9)0.46144 (18.2)1.000152 (62.0)0.336
History of GERD
 No92 (26.2)42 (45.7)13 (14.1)25 (26.9)62 (67.4)
 Yes258 (73.8)139 (53.9)0.17555 (21.3)0.16737 (15.0)0.017159 (60.7)0.211
History of Barrett's esophagus
 No110 (31.1)49 (44.5)14 (12.7)27 (24.8)75 (68.2)
 Yes244 (68.9)134 (54.9)0.07156 (23.0)0.03035 (14.9)0.034137 (57.3)0.059
Charlson Comorbidity Index
 Low (CCI 0–1)134 (37.8)75 (56.0)27 (20.1)26 (19.7)80 (60.6)
 Intermediate (CCI 2–5)151 (42.7)73 (48.3)30 (19.9)26 (17.9)90 (60.0)
 High (CCI >5)69 (19.5)35 (50.7)0.4313 (18.8)110 (14.9)0.73142 (62.7)0.948
Tumor location
 Mid/proximal esophagus7 (2.0)4 (57.1)2 (28.6)2 (33.3)4 (66.7)
 Distal esophagus96 (27.4)50 (52.1)23 (24.0)16 (17.2)54 (56.8)
 GE junction247 (70.6)126 (51.0)0.66144 (17.8)0.30144 (18.3)0.612151 (62.1)0.679
Tumor stage (AJCC7)
 T1138 (39.1)88 (63.8)42 (30.4)22 (17.1)56 (42.1)
 T236 (10.2)17 (47.2)5 (13.9)7 (20.0)23 (63.9)
 T3174 (49.3)75 (43.1)22 (12.6)32 (18.5)131 (75.7)
 T45 (1.4)2 (40.0)0.0031 (20.0)0.0011 (20.0)0.9501 (20.0)<0.001
Tumor size
 Median (IQR)3.7 (2.4–5.5)3.780.0403.40.0144.50.1864.5<0.001
Tumor grade
 Well-differentiated24 (6.8)22 (91.7)13 (54.2)1 (4.2)5 (20.8)
 Moderately differentiated145 (41.0)78 (53.8)33 (22.8)23 (16.5)80 (56.7)
 Poorly differentiated185 (52.2)83 (44.9)<0.00124 (13.0)<0.00138 (21.0)0.105127 (69)<0.001
Node stage (AJCC7)
 N0140 (39.7)79 (56.4)36 (25.7)20 (15.3)51 (37.8)
 N180 (22.7)39 (48.8)12 (15.0)12 (15)54 (66.7)
 N262 (17.6)26 (41.9)10 (16.1)12 (19.4)44 (71.0)
 N371 (20)38 (53.5)0.26312 (16.9)0.18517 (24.3)0.37962 (88.6)<0.001
Metastasis stage
 M0341 (96.6)177 (51.9)69 (20.2)59 (17.8)203 (60.2)
 M112 (3.4)5 (41.7)0.4851 (8.0)0.4733 (25.0)0.4608 (72.2)0.537
Final AJCC7 stage group
 Stage I116 (33.0)74 (63.8)36 (31.0)15 (14.0)41 (36.9)
 Stage II53 (15.0)22 (41.5)7 (13.2)12 (22.6)27 (50.9)
 Stage III171 (48.6)52 (47.3)26 (15.2)31 (18.2)134 (77.9)
 Stage IV12 (3.4)5 (41.7)0.0091 (8.3)0.0033 (25.0)0.5058 (72.7)<0.001

NOTE: PD-L2+, >1 core: 1 or more cores have moderate-to-strong epithelial PD-L2 expression; PD-L2+, all cores: all evaluated cores have moderate-to-strong epithelial PD-L2 expression; PD-L1+, any positive immune cell; PD-1+, any positive lymphocyte. P < 0.05 is considered statistically significant.

Abbreviations: AJCC: American Joint Committee on Cancer; GE, gastroesophageal; GERD, gastroesophageal reflux disease; IQR, interquartile range.